Endothelial dysfunction: A marker of atherosclerotic risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 2, 2003, Pages 168-175

  Bonetti, Piero O ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atherosclerosis; Cardiovascular event; Endothelial dysfunction; Prognosis; Risk factor

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CARDIOVASCULAR AGENT; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FOLIC ACID; GLUTATHIONE; HYPOCHOLESTEROLEMIC AGENT; STATINE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; ESTROGEN THERAPY; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; VITAMIN SUPPLEMENTATION;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROGNOSIS; RISK FACTORS; SYNDROME;

EID: 0037324283     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000051384.43104.FC     Document Type: Review

References (94)

1. Ross R. Atherosclerosis; an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997;80:11-I-16-I.
3. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86(suppl III):III-12-II-19.
4. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34:631-638.
5. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
6. Hasdai D, Lerman A. The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz. 1999;24:544-547.
7. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71B-74B.
8. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.
9. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535-1539.
10. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257-265.
11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
12. Tomasian D, Keaney JF Jr, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res. 2000;47:426-435.
13. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Freeradical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999;56: 471-478.
14. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
15. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468-1474.
16. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
17. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KRA, Quyyumi A. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
18. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567-1572.
19. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000;902:230-239.
20. Vogel RA, Corretti MC. Estrogens, progestins, and heart disease: can endothelial function divine the benefit? Circulation. 1998;97:1223-1226.
21. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991;84:1984-1992.
22. McLenachan JM, Vita J, Fish DR, Teasure CB, Cox DA, Ganz P, Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branching points. Circulation. 1990;82:1169-1173.
23. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83: 391-401.
24. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92:320-326.
25. Gage JE, Hess OM, Murakami T, Ritter M. Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986;73:865-876.
26. Gordon JB, Ganz P. Nabel EG, Fish RD, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989; 83:1946-1952.
27. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325:1551-1556.
28. Motz W, Vogt M, Rabenau O, Scheler S, Luckhoff A, Strauer BE. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol. 1991;68:996-1003.
29. Quyyumi AA, Cannon RO III. Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation. 1992;86:1864-1871.
30. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664.
31. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995; 91:2345-2352.
32. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96:3390-3395.
33. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
34. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
35. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674-682.
36. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651-4655.
37. De Catarina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
38. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
39. Peng HB, Libby P. Liao JK. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem. 1995;270: 14214-14219.
40. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation. 1994;90:5-11.
41. McGorisk GM, Treasure CB. Endothelial dysfunction in coronary artery disease. Curr Opin Cardiol. 1996;11:341-350.
42. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M, Chiariello M. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324:641-648.
43. Yang ZH, Richard V. von Segesser L, Bauer E, Stulz P, Turina M, Lüscher TF. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonine in human arteries: a new mechanism of vasospasm? Circulation. 1990;82:188-195.
44. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 1995;92:2426-2431.
45. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
46. Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941-947.
47. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
48. Hedblad B, Ögren M, Janzon L, Isacsson SO, Lindell SE. Low pulse-wave amplitude during reactive leg hyperemia: an independent, early marker for ischaemic heart disease and death: results from the 21-year follow-up of the prospective cohort study 'Men born in 1914,' Malmö, Sweden. J Intern Med. 1994;236:161-168.
49. Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, Ganz P. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension. 2001;38:1049-1053.
50. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolino AP. Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002;105:213-217.
51. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
52. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
53. Vogel RA. Cholesterol lowering and endothelial function. Am J Med. 1999;107:479-487.
54. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002;62:265-284.
55. Celermajer DS, Sorensen KE. Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149-2155.
56. Vita JA, Keaney JF. Hormone replacement therapy and endothelial function: the exception that proves the rule? Arterioscler Thromb Vasc Biol. 2001;21:1867-1869.
57. Doshi SN, McDowell IFW, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 2001;21:1196-1202.
58. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342:454-460.
59. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J. In press.
60. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
61. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
62. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
63. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
64. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
65. Kansui Y, Fujii K, Goto K, Abe I, Iida M. Angiotensin II receptor antagonist improves age-related endothelial dysfunction. J Hypertens. 2002;20:439-446.
66. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL. Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study. Circulation. 1996;94: 258-265.
67. Prasad A, Narayanan S, Husain S, Padder F, Waclawiw M, Epstein N, Quyyumi AA. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation. 2000;102:35-41.
68. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
69. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1999;33:1506-1511.
70. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study). J Am Coll Cardiol. 2000;35:60-66.
71. Mullen MJ, Clarkson P, Donald AE, Thomson H, Thorne SA, Powe AJ, Furuno T, Bull T, Deanfield JE. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized. double-blind study. J Am Coll Cardiol. 1998;31:1330-1335.
72. Prasad A, Halcox JPJ, Waclawiw MA, Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol. 2001;38:1089-1095.
73. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawiw MA, Ellahham S, Quyyumi AA. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101:2349-2354.
74. Prasad A, Andrews NP, Padder FA, Husain M, Quyyumi AA. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J Am Coll Cardiol. 1999;34:507-514.
75. Andrews NP, Prasad A, Quyyumi AA. N-Acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37: 117-123.
76. Duffy SJ, Gokce N, Holbrook M, Hunter LM, Biegelsen ES, Huang A, Keaney JF, Vita JA. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol. 2001;280:H528-H534.
77. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Stocker R, Celerrnajer DS. Oral vitamin C and endothelial function in smokers: short term improvement, but no sustained beneficial effect. J Am Coll Cardiol. 2000;35:1616-1621.
78. Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic Biol Med. 2000;28:1806-1814.
79. Visioli F. Effects of vitamin E on the endothelium: equivocal? α-tocopherol and endothelial dysfunction Cardiovasc Res. 2001;51:198-201.
80. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123-2128.
81. Verhaar MC, Honing MLH, van Dam T, Zwart M, Koomans HA, Kastelein JJP, Rabelink TJ. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752-760.
82. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
83. Van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG, on behalf of the REGRESS Study Group. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503-1505.
84. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.
85. Prasad A, Mincemoyer R, Quyyumi AA. Anti-ischemic effects of angiotensin-converting enzyme inhibition in hypertension. J Am Coll Cardiol. 2001;38:1116-1122.
86. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89-95.
87. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 6 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;2053:23-33.
88. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
89. Cannon RO III. Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? Circulation. 2000;102:820-822.
90. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: ox marks the spot. Circulation. 2001;104:2638-1640.
91. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
92. Koh KK, Schenke WH. Waclawiw MA, Csako G, Cannon RO III. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation. 2002;105:1531-1533.
93. Herrington DM, Espeland MA, Crouse JR III, Robertson J, Riley WA, McBurnie MA, Burke GL. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001;21:1955-1961.
94. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.